Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Published:2017-06-22 Issue:25 Volume:129 Page:3322-3331
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Gardner Rebecca A.¹²³^ORCID,Finney Olivia¹,Annesley Colleen¹²³^ORCID,Brakke Hannah¹,Summers Corinne¹²,Leger Kasey¹,Bleakley Marie²⁴,Brown Christopher¹,Mgebroff Stephanie¹,Kelly-Spratt Karen S.¹,Hoglund Virginia¹,Lindgren Catherine¹,Oron Assaf P.³,Li Daniel⁵,Riddell Stanley R.⁴⁶,Park Julie R.¹²³,Jensen Michael C.¹²⁴

Affiliation:

1. Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, WA;

2. Department of Pediatrics, University of Washington, Seattle, WA;

3. Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA;

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

5. Clinical Statistics Group, Juno Therapeutics, Inc., Seattle, WA; and

6. Department of Medicine, University of Washington, Seattle, WA

Abstract

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/25/3322/1364282/blood769208.pdf

Reference19 articles.

1. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

2. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial;Lee;Lancet,2015

3. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients;Turtle;J Clin Invest,2016

4. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells;Turtle;Sci Transl Med,2016

5. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia;Porter;Sci Transl Med,2015

Cited by 887 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients;Leukemia Research;2024-10

2. Sclerotic chronic cutaneous graft-versus-host-disease following pseudoallogeneic chimeric antigen receptor T-cell therapy;JAAD Case Reports;2024-10

3. Efficient Capture and Traceless Release of Functional CD8⁺ T Cells with a Microfluidic Chip for Enhanced In Vitro and In Vivo CD4-CAR Transduction;Analytical Chemistry;2024-09-13

4. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

5. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors;Journal of Clinical Oncology;2024-09-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3